GTR Test Accession:
Help
GTR000611981.2
Last updated in GTR:
2023-09-28
View version history
GTR000611981.2,
last updated:
2023-09-28
GTR000611981.1,
registered in GTR:
2023-09-26
Last annual review date for the lab: 2024-08-13
LinkOut
At a Glance
Methods (1):
Help
Molecular Genetics - Sequence analysis of the entire coding region: Next-Generation (NGS)/Massively parallel sequencing (MPS)
Target population: Help
Not provided
Clinical validity:
Help
Not provided
Clinical utility:
Help
Establish or confirm diagnosis
Ordering Information
Offered by:
Help
Who can order: Help
- Health Care Provider
Test Order Code:
Help
10111
View other test codes
View other test codes
Lab contact:
Help
Contact Policy:
Help
Laboratory can only accept contact from health care providers. Patients/families are encouraged to discuss genetic testing options with their health care provider.
How to Order:
Help
Test development:
Help
Test developed by laboratory (no manufacturer test name)
Informed consent required:
Help
Decline to answer
Pre-test genetic counseling required:
Help
Decline to answer
Post-test genetic counseling required:
Help
Decline to answer
Recommended fields not provided:
Specimen source,
Test strategy
Conditions
Help
Total conditions: 56
| Condition/Phenotype | Identifier |
|---|
Test Targets
Genes
Help
Total genes: 69
| Gene | Associated Condition | Germline or Somatic | Allele (Lab-provided) | Variant in NCBI |
|---|
Methodology
Total methods: 1
Method Category
Help
Test method
Help
Instrument
Sequence analysis of the entire coding region
Next-Generation (NGS)/Massively parallel sequencing (MPS)
Applied Biosystems 3730 capillary sequencing instrument
Clinical Information
Test purpose:
Help
Diagnosis;
Mutation Confirmation
Clinical utility:
Help
Variant Interpretation:
What is the protocol for interpreting a variation as a VUS?
Help
Practice guidelines for the Interpretation and Reporting of Unclassified Variants (UVs) in Clinical Molecular Genetics. Prepared and edited by Jennie Bell, Danielle Bodmer, Erik Sistermans and Simon C Ramsden
Practice guidelines for the Interpretation and Reporting of Unclassified Variants (UVs) in Clinical Molecular Genetics. Prepared and edited by Jennie Bell, Danielle Bodmer, Erik Sistermans and Simon C Ramsden
Are family members with defined clinical status recruited to assess significance of VUS without charge?
Help
No.
No.
Will the lab re-contact the ordering physician if variant interpretation changes?
Help
Yes. We systematically (every 6-8 months) re-evaluated the data and re-contact the physician in case of new pathogenic findings
Yes. We systematically (every 6-8 months) re-evaluated the data and re-contact the physician in case of new pathogenic findings
Research:
Is research allowed on the sample after clinical testing is complete?
Help
In interesting cases, we perform research after clinical testing is complete and we require a research consent inform for that purpose
In interesting cases, we perform research after clinical testing is complete and we require a research consent inform for that purpose
Recommended fields not provided:
Clinical validity,
Target population,
Sample negative report,
Sample positive report
Technical Information
Test Procedure:
Help
If we found a pathogenic variation, we perform an independent analysis to confirm the finding
Test Confirmation:
Help
If we found a pathogenic variation, we perform an independent analysis to confirm the finding
Availability:
Help
Tests performed
Entire test performed in-house
Entire test performed in-house
Analytical Validity:
Help
99.9%. If we found a pathogenic variation, we perform an independent analysis to confirm the finding
Proficiency testing (PT):
Is proficiency testing performed for this test?
Help
Yes
Method used for proficiency testing: Help
Inter-Laboratory
PT Provider: Help
European Molecular Genetics Quality Network, EMQN
Yes
Method used for proficiency testing: Help
Inter-Laboratory
PT Provider: Help
European Molecular Genetics Quality Network, EMQN
VUS:
Software used to interpret novel variations
Help
Varsome
Laboratory's policy on reporting novel variations Help
Novel variations suspected to be pathogenic are included in the routine reports. VUS are also reported. Non pathogenic variations are NOT reported as well as VUS with MAF>3%
Varsome
Laboratory's policy on reporting novel variations Help
Novel variations suspected to be pathogenic are included in the routine reports. VUS are also reported. Non pathogenic variations are NOT reported as well as VUS with MAF>3%
Recommended fields not provided:
Assay limitations,
Description of internal test validation method,
Citations for Analytical validity,
Description of PT method,
Major CAP category, CAP category, CAP test list
Regulatory Approval
FDA Review:
Help
Not provided
Additional Information
Suggested reading:
Clinical resources:
Molecular resources:
Practice guidelines:
Consumer resources:
IMPORTANT NOTE:
NIH does not independently verify information submitted to GTR; it relies on submitters to provide information that is accurate and not misleading.
NIH makes no endorsements of tests or laboratories listed in GTR. GTR is not a substitute for medical advice.
Patients and consumers
with specific questions about a genetic test should contact a health care provider or a genetics professional.